Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Oxnard, CA
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Oxnard, CA
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Chicago, IL
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Lafayette, IN
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Lafayette, IN
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Baton Rouge, LA
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Annapolis, MD
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Annapolis, MD
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Boston, MA
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Danvers, MA
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Danvers, MA
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Omaha, NE
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Lake Success, NY
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Lake Success, NY
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Canton, OH
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Dover, OH
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Dover, OH
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Hershey, PA
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Hershey, PA
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Research Site
mi
from
Hilton Head, SC
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Research Site
mi
from
Hilton Head, SC
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
Clinical Research Facility
mi
from
Corpus Christi, TX
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
Clinical Research Facility
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/5/2014
mi
from
Ottawa,
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer
A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/5/2014
mi
from
Ottawa,
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
University of California at San Diego Moores Cancer Center
mi
from
San Diego, CA
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
University of California at San Diego Moores Cancer Center
mi
from
San Diego, CA
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
University of Colorado Hospital
mi
from
Aurora, CO
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
Yale University
mi
from
New Haven, CT
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
University of Chicago Medical Center
mi
from
Chicago, IL
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
Mass General Hospital (MGH)
mi
from
Boston, MA
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
Mass General Hospital (MGH)
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
Univ of Pennsylvania
mi
from
Philadelphia, PA
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated:  4/11/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Status: Enrolling
Updated: 4/11/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
A Phase I/II Trial of AMG 102 and Erlotinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/14/2014
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
A Phase I/II Trial of AMG 102 and Erlotinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/14/2014
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Validation of the MiCK Assay
Mayo Clinic Validation of the MiCK Assay
Status: Enrolling
Updated:  4/18/2014
Mayo Validation Support Services 3050 Superior Drive NW
mi
from
Rochester, MN
Validation of the MiCK Assay
Mayo Clinic Validation of the MiCK Assay
Status: Enrolling
Updated: 4/18/2014
Mayo Validation Support Services 3050 Superior Drive NW
mi
from
Rochester, MN
Click here to add this to my saved trials
A Protocol of Irinotecan for Carcinoma of the Lung
A Non-randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced ISG15-positive Non-small Cell Carcinoma of the Lung
Status: Enrolling
Updated:  4/28/2014
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
A Protocol of Irinotecan for Carcinoma of the Lung
A Non-randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced ISG15-positive Non-small Cell Carcinoma of the Lung
Status: Enrolling
Updated: 4/28/2014
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated:  5/13/2014
North Carolina Cancer Hospital at U of North Carolina at CH
mi
from
Chapel Hill, NC
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated: 5/13/2014
North Carolina Cancer Hospital at U of North Carolina at CH
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated:  5/13/2014
Rex Cancer Center at Rex Hospital
mi
from
Raleigh, NC
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated: 5/13/2014
Rex Cancer Center at Rex Hospital
mi
from
Raleigh, NC
Click here to add this to my saved trials
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated:  5/13/2014
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
Status: Enrolling
Updated: 5/13/2014
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Free Fatty Acid Metabolite Biomarkers for Cancer
Status: Enrolling
Updated:  5/14/2014
Cleveland Clinic
mi
from
Cleveland, OH
Free Fatty Acid Metabolite Biomarkers for Cancer
Status: Enrolling
Updated: 5/14/2014
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/19/2014
Cancer Research And Biostatistics Clinical Trials Consortium
mi
from
Seattle, WA
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/19/2014
Cancer Research And Biostatistics Clinical Trials Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/19/2014
Providence Cancer Center
mi
from
Portland, OR
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/19/2014
Providence Cancer Center
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/19/2014
The University of Arizona Cancer Center
mi
from
Tuscon, AZ
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/19/2014
The University of Arizona Cancer Center
mi
from
Tuscon, AZ
Click here to add this to my saved trials
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/19/2014
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/19/2014
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Roswell Park Cancer Institute
mi
from
Buffalo, NY
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated:  6/27/2014
Scottsdale Healthcare
mi
from
Scottsdale, AZ
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer
Status: Enrolling
Updated: 6/27/2014
Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
Pilot Study of Dual-Energy Computed Tomography in Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  8/29/2014
Rush University Medical Center
mi
from
Chicago, IL
Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
Pilot Study of Dual-Energy Computed Tomography in Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 8/29/2014
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Cardiopulmonary Research Science & Technology Institute
mi
from
Dallas, TX
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Cardiopulmonary Research Science & Technology Institute
mi
from
Dallas, TX
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Geisinger Medical Center
mi
from
Danville, PA
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Group Health Research Institute
mi
from
Seattle, WA
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Group Health Research Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Henry Ford Hospital
mi
from
Detroit, MI
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Intermountain Healthcare
mi
from
Murray, UT
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Intermountain Healthcare
mi
from
Murray, UT
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Kaiser Permanente Northern California
mi
from
San Francisco, CA
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Kaiser Permanente Northern California
mi
from
San Francisco, CA
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Lahey Hospital and Medical Center
mi
from
Burlington, MA
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Lahey Hospital and Medical Center
mi
from
Burlington, MA
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
Mayo Clinic Rochester
mi
from
Rochester, MN
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
North East Alabama Regional Medical Center
mi
from
Anniston, GA
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
North East Alabama Regional Medical Center
mi
from
Anniston, GA
Click here to add this to my saved trials
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated:  9/18/2014
University of Cincinnati
mi
from
Cincinnati, OH
Identification of a Plasma Proteomic Signature for Lung Cancer
Identification of a Plasma Proteomic Signature for Lung Cancer
Status: Enrolling
Updated: 9/18/2014
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials